(Q52167582)

26 April 2018

title

Enalapril and valsartan improve cyclosporine A-induced vascular dysfunction in spontaneously hypertensive rats. (English)

1 reference

26 April 2018

1 reference

1 reference

Lassila M

1

1 reference

26 April 2018

Finckenberg P

2

1 reference

26 April 2018

Pere AK

3

1 reference

26 April 2018

Vapaatalo H

4

1 reference

26 April 2018

Nurminen ML

5

1 reference

26 April 2018

language of work or name

English

0 references

publication date

1 June 2000

1 reference

26 April 2018

European Journal of Pharmacology

published in

1 reference

26 April 2018

volume

398

1 reference

26 April 2018

issue

1

1 reference

26 April 2018

page(s)

99-106

1 reference

26 April 2018

Effects of cyclosporin A on the synthesis, excretion, and metabolism of endothelin in the rat

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Endothelial and vascular smooth muscle function after chronic treatment with cyclosporin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Vasomotor responses in cyclosporin A-treated rats after chronic angiotensin blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

7 January 2021

The endothelial organ

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Vascular remodeling: the role of angiotensin-converting enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Cyclosporine produces endothelial dysfunction by increased production of superoxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Cyclosporine, but not FK506, selectively induces renal and coronary artery smooth muscle contraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Mechanisms of the endothelial toxicity of cyclosporin A. Role of nitric oxide, cGMP, and Ca2+

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Increased endothelial gene expression of angiotensin AT1A receptor in cyclosporine induced hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Studies in chronic cyclosporine nephrotoxicity in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Angiotensin tachyphylaxis and its reversal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Calcium in ischemic cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Effects of dietary sodium and magnesium on cyclosporin A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Effects of ACE inhibition on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on a high-sodium diet.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Role of nitric oxide in cyclosporine A-induced hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Detrimental effect of dietary sodium and beneficial effect of dietary magnesium on glomerular changes in cyclosporin-A-treated spontaneously hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Tissue- and subtype-specific modulation of angiotensin II receptors by chronic treatment with cyclosporin A, angiotensin-converting enzyme inhibitors and AT1 antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Endothelium-dependent relaxation in the isolated rat kidney: impairment by cyclosporine A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Cyclosporine-induced hypertension after transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

Regional differences in vasculotoxic effects of cyclosporin in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900282-X

10.1016/S0014-2999(00)00282-X

7 January 2021

Identifiers

DOI

1 reference

26 April 2018

1 reference

26 April 2018